Sign in
WithdrawnPhase 1/2

Adoptive Treatment of Advanced Hepatocellular Carcinoma With Allogeneic γδ-T Cells

Key facts

Who runs it
Guangdong GD Kongming Biotech LLC
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Withdrawn
Phase
Phase 1/2
Started
1 Nov 2021
Ended
31 Oct 2024
Type of study
Interventional
Treatments tested
  • GDKM-100 injection
Record updated
18 January 2023
Why it stopped
COVID1-19 pandemic

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (15)Hide the full registry criteria

Who can take part

  • Age is 18-75 years old, and gender is unlimited
  • HCC was confirmed by pathological or clinical examination
  • Patients with stage CNLCIII, IV primary HCC who are receiving second-line treatment / unable to receive existing treatments, or CNLCI and II of primary HCC patients who are unable to receive existing treatments
  • Male subjects with partner women of childbearing age must have reliable, effective methods of contraception starting from the signing of the informed consent form until 120 days after the last dose of the study drug. Male subjects with a pregnant spouse must use condoms without other contraceptive methods
  • Participants volunteered to join the study, signed an informed consent, had good compliance, and cooperated with the follow-up

Who cannot take part

  • Accept other cellular or immune clinical experiments within 8 weeks before enrollment
  • Hormone use during cell therapy: dexamethasone dose exceeds 2mg / day during immunotherapy
  • Gastrointestinal bleeding, refractory ascites, hepatic encephalopathy, or hepatorenal syndrome
  • Immunological deficiency, a known immunosuppressive disease or HIV
  • Active infection, unexplained fever
  • Serious or unstable heart, lung, kidney and hematopoietic system diseases
  • Autoimmune diseases, such as rheumatoid arthritis
  • Neurological diseases, diffuse leptomeningeal diseases; combined with neurodegenerative diseases
  • The subject had a known history of psychotropic substance abuse or drug use; he had stopped drinking Patients can be enrolled; 11 In the judgment of the investigator, the subject has other factors that may cause the forced termination of the study, such as other serious diseases or serious abnormal laboratory examination or other family or social factors that will affect the subject's safety of the subject, or the collection of trial data and samples
  • Pregnant or lactating women

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Brief Summary: In this study, effects of γδ T cells on Advanced hepatocyte carcinoma The goal of this clinical trial is to learn about effects of allogeneic γδ T therapy in advanced hepatocyte carcinoma patients.

Read full original descriptionShow less

The main question it aims to answer is:Will advanced hepatocyte carcinoma patients be benefit from allogeneic γδ T therapy? Participants will received GDKM-100injection (allo-γδ T Cells) Infusion every two weeks.

The group in the trial

  • GDKM-100 injectionTreatment being tested

    In this trial, the patients will receive multiple high-activity γδ T cell immunotherapies.The trial is divided into two parts: Part 1 is a multiple-dose escalation trial consisting of 3 dose groups (2×10\^8 cells/person, 5×10\^8 cells/person, 10×10\^8 cells/person at 1-3 infusion, 4-6 infusion and 7-9 infusion), with 9 patients planned to be enrolled. Part 2 is a single dose trial in which doctor and the PI evaluates whether to give the rest patients to receive the 10×10\^8 cells/person infusions based on available safety data. The check indexes are CT scan,intestinal flora detection and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Clinical Study on Adoptive Treatment of Advanced Hepatocellular Carcinoma With Allogeneic γδ-T Cells
Record updated
18 January 2023